{"id":386616,"date":"2020-11-23T08:03:31","date_gmt":"2020-11-23T13:03:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=386616"},"modified":"2020-11-23T08:03:31","modified_gmt":"2020-11-23T13:03:31","slug":"ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/","title":{"rendered":"Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference"},"content":{"rendered":"

<\/p>\n

Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference<\/b><\/p>\n

BEDFORD, Mass.–(BUSINESS WIRE<\/a>)–
\nOcular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held from December 1 to December 3, 2020.\n<\/p>\n

\nIn addition to a fireside chat, the management team will host virtual investor meetings on Wednesday, December 2nd<\/sup> at the conference. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their Piper Sandler representative.\n<\/p>\n

\nA webcast of the pre-recorded fireside chat presentation has been made available ahead of the conference and can be accessed by visiting the Investors section of the Company\u2019s website at investors.ocutx.com. It will be available for replay for 90 days.\n<\/p>\n

About Ocular Therapeutix, Inc. <\/b><\/p>\n

\nOcular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix\u2019s first commercial drug product, DEXTENZA, is FDA-approved for the treatment of ocular inflammation and pain following ophthalmic surgery. Ocular Therapeutix recently completed a Phase 3 clinical trial evaluating DEXTENZA for the treatment of ocular itching associated with allergic conjunctivitis. Ocular Therapeutix\u2019s earlier stage development assets currently in Phase 1 clinical trials include OTX-TIC (travoprost intracameral implant) for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension and OTX-TKI (axitinib intravitreal implant) for the treatment of wet AMD and other retinal diseases. Ocular Therapeutix is currently evaluating OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease in a Phase 2 clinical trial. Also, Ocular Therapeutix is currently developing OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease and, in collaboration with Regeneron, OTX-AFS (aflibercept suprachoroidal injection) as an extended-delivery formulation of aflibercept for the treatment of retinal diseases. Ocular Therapeutix’s first product, ReSure\u00ae Sealant, is an FDA-approved device to seal corneal incisions following cataract surgery.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20201123005610\/en\/<\/a><\/span><\/p>\n

Investors
\n<\/b>
Ocular Therapeutix
\n
Donald Notman
\n
Chief Financial Officer
\n
dnotman@ocutx.com <\/a><\/p>\n

Media
\n<\/b>
Ocular Therapeutix
\n
Scott Corning
\n
Senior Vice President, Commercial
\n
scorning@ocutx.com
\n<\/a>
or
\n
Westwicke, an ICR Company
\n
Chris Brinzey, 339-970-2843
\n
chris.brinzey@westwicke.com<\/a><\/p>\n

KEYWORDS:<\/b> Massachusetts United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Research FDA Clinical Trials Biotechnology General Health Pharmaceutical Health Optical Science Other Science<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference BEDFORD, Mass.–(BUSINESS WIRE)– Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held from December 1 to December 3, 2020. In addition to a fireside chat, the management team will host virtual investor meetings on Wednesday, December 2nd at the conference. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their Piper Sandler representative. A webcast of the pre-recorded fireside chat presentation has been made available ahead of the … <\/p>\n

Continue reading “Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-386616","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nOcular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference BEDFORD, Mass.–(BUSINESS WIRE)– Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held from December 1 to December 3, 2020. In addition to a fireside chat, the management team will host virtual investor meetings on Wednesday, December 2nd at the conference. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their Piper Sandler representative. A webcast of the pre-recorded fireside chat presentation has been made available ahead of the … Continue reading "Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-23T13:03:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201123005610r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference\",\"datePublished\":\"2020-11-23T13:03:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/\"},\"wordCount\":439,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201123005610r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/\",\"name\":\"Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201123005610r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2020-11-23T13:03:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201123005610r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20201123005610r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk","og_description":"Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference BEDFORD, Mass.–(BUSINESS WIRE)– Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference being held from December 1 to December 3, 2020. In addition to a fireside chat, the management team will host virtual investor meetings on Wednesday, December 2nd at the conference. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their Piper Sandler representative. A webcast of the pre-recorded fireside chat presentation has been made available ahead of the … Continue reading \"Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-23T13:03:31+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201123005610r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference","datePublished":"2020-11-23T13:03:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/"},"wordCount":439,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201123005610r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/","name":"Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201123005610r1&sid=flmnd&distro=nx&lang=en","datePublished":"2020-11-23T13:03:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201123005610r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20201123005610r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ocular-therapeutix-to-present-at-the-piper-sandler-32nd-annual-virtual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ocular Therapeutix\u2122 to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=386616"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/386616\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=386616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=386616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=386616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}